Annovis Bio will present two research presentations at the CTAD conference, highlighting biomarker data for buntanetap in treating Alzheimer's and Parkinson's diseases, focusing on potential disease-modifying therapeutic approaches.
Annovis Bio, Inc. (ANVS)
Common Stock · Currency in USD · XNYS
Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.
Company Info
SIC2834
Composite FIGIBBG00PN9XD40
CIK0001477845
IPOJan 29, 2020
Sectorpharmaceutical preparations
Highlights
Market Cap$64.65M
EPS-$1.48
P/E Ratio-2.23
Revenue$NaN
Gross Profit$0.00
Net Income-$29.05M
Employees7
WSO28,355,262
Phone484-875-3192
Websitehttps://www.annovisbio.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Annovis Bio, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Annovis Bio, Inc. (ANVS) has returned -33.91% so far this year and 80.95% over the past 12 months. Looking at the last ten years, ANVS has achieved an annualized return of -10.12%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
ANVS
1M-12.64%
6M3.64%
YTD-33.91%
1Y80.95%
5Y-38.94%
10Y-10.12%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Annovis Bio, Inc. (ANVS) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -21.74% | 0.75% | -11.16% | |||||||||
| 2025 | -3.37% | -54.81% | -20.63% | -0.67% | 60.96% | -6.87% | 24.66% | -14.44% | -9.61% | 3.96% | 145.19% | -31.35% |
| 2024 | -41.84% | -27.23% | 35.23% | -53.58% | 19.96% | -12.73% | 55.43% | -9.90% | -3.36% | 13.45% | -28.99% | -25.48% |
| 2023 | 20.58% | -0.70% | -9.72% | 8.33% | -9.66% | 11.29% | -2.54% | -9.42% | -25.22% | -30.27% | 28.44% | 114.94% |
| 2022 | -15.72% | -7.55% | -5.05% | -30.59% | -2.96% | 23.26% | -0.35% | 0.26% | 21.08% | -8.46% | 4.43% | 0.98% |
| 2021 | 28.61% | 156.21% | 0.72% | -23.23% | 103.15% | 83.61% | -60.78% | 4.02% | -14.99% | -15.68% | -9.58% | -26.78% |
| 2020 | -1.66% | -32.17% | -36.84% | 40.00% | 30.97% | -8.23% | 31.82% | -16.08% | 6.18% | -7.13% | 29.76% | 28.01% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Annovis Bio, Inc. (ANVS) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ANVS compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Annovis Bio, Inc. volatility is 5.95%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M | 8.12M |
| Equity Attributable To Parent (USD) | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M | 7.54M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - |
| Equity (USD) | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M | 7.54M |
| Noncurrent Liabilities (USD) | 595.00K | 737.00K | 13.68M | - | - | - |
| Other Current Liabilities (USD) | 618.66K | 1.21M | 2.89M | 3.18M | 105.67K | 220.03K |
| Wages (USD) | 426.20K | 364.72K | 96.85K | 556.83K | 712.77K | 16.49K |
| Accounts Payable (USD) | 2.59M | 2.31M | 1.29M | 3.96M | 688.07K | 341.86K |
| Current Liabilities (USD) | 3.64M | 3.88M | 4.28M | 7.70M | 1.51M | 578.38K |
| Liabilities (USD) | 4.23M | 4.62M | 17.96M | 7.70M | 1.51M | 578.38K |
| Noncurrent Assets (USD) | - | - | - | - | - | - |
| Current Assets (USD) | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M | 8.12M |
| Assets (USD) | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M | 8.12M |
News and Insights
The Alzheimer's disease market is expected to grow significantly between 2025-2034, driven by emerging therapies targeting disease mechanisms and improved diagnostic capabilities, with the US market representing approximately 50% of the total market size.
Annovis Bio, a late-stage clinical drug platform company, will present data from its latest Phase 3 Parkinson's disease and Phase 2/3 Alzheimer's disease studies at the AD/PD™ 2025 conference in Vienna.
LEQEMBI, an Alzheimer's disease treatment developed by Biogen and Eisai, has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. The Alzheimer's disease market is highly competitive, with numerous companies advancing therapies in the pipeline.
The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.
Annovis Bio, a late-stage clinical drug platform company, announced that its CEO will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference, highlighting the progress of the pivotal Phase 3 trial in early Alzheimer's disease and strategic initiatives toward a New Drug Application for buntanetap.
Annovis Bio Inc. has announced the start of a pivotal Phase 3 study evaluating its drug candidate buntanetap for the treatment of early Alzheimer's disease. The study aims to assess the safety and efficacy of buntanetap in improving cognition and functional ability in patients.
Annovis Bio, a clinical-stage biopharmaceutical company, announced its intention to offer common stock and warrants in a public offering. The company plans to use the net proceeds for working capital and the continued development of its lead compound, Buntanetap, for the treatment of neurodegenerative diseases.
Annovis Bio, a clinical-stage drug platform company, is hosting an investor webcast on December 11, 2024, to provide updates on its Phase 3 studies for Parkinson's and Alzheimer's diseases, regulatory milestones, financial overview, and strategic outlook for 2025.
Pharmaceutical companies are exploring innovative drug combinations to address unmet medical needs, including Alzheimer's disease. Annovis Bio is leading the way with its drug buntanetap, which is being tested in combination with other approved drugs like Trulicity and Viagra to enhance cognitive function. This approach holds promise for providing new hope to patients suffering from neurodegenerative diseases.